LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerEliza Vakana, Louis F. Stancato|Oncotarget|2016Cited by 68
Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing CellsEliza Vakana, Leonidas C. Platanias|PLoS ONE|2013Cited by 17